Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Savita Bakhshi Anand"'
Autor:
Cassidy A. Gutner PhD, Marc van der Valk MD, PhD, Joaquin Portilla MD, Eliette Jeanmaire MD, Leïla Belkhir MD, PhD, Thomas Lutz MD, Rebecca DeMoor MSc, Rekha Trehan BSc, Jenny Scherzer MBA, MSc, Miguel Pascual-Bernáldez PharmB, Mounir Ait-Khaled PhD, Beatriz Hernandez PharmD, PhD, Annemiek de Ruiter MBBS, FRCP, Savita Bakhshi Anand PhD, Emma L. Low PhD, Monica Hadi PhD, Nicola Barnes MA, Nick Sevdalis PhD, Perry Mohammed MBBS, Maggie Czarnogorski MD, MPH
Publikováno v:
Journal of the International Association of Providers of AIDS Care, Vol 23 (2024)
Introduction CARISEL is an implementation–effectiveness “hybrid” study examining the perspectives of people living with HIV-1 (patient study participants [PSPs]) on cabotegravir (CAB) plus rilpivirine (RPV) long-acting (LA) dosed every 2 months
Externí odkaz:
https://doaj.org/article/5d90730f2456430790ded91fab079d5b
Autor:
Cassidy A. Gutner, Laurent Hocqueloux, Celia Jonsson‐Oldenbüttel, Linos Vandekerckhove, Berend J. vanWelzen, Laurence Slama, María Crusells‐Canales, Julián Olalla Sierra, Rebecca DeMoor, Jenny Scherzer, Mounir Ait‐Khaled, Gilda Bontempo, Martin Gill, Natasha Patel, Ronald D'Amico, Kai Hove, Bryan Baugh, Nicola Barnes, Monica Hadi, Emma L. Low, Savita Bakhshi Anand, Alison Hamilton, Harmony P. Garges, Maggie Czarnogorski
Publikováno v:
Journal of the International AIDS Society, Vol 27, Iss 7, Pp n/a-n/a (2024)
Abstract Introduction Cabotegravir plus rilpivirine (CAB + RPV) is the first complete long‐acting (LA) regimen recommended for maintaining HIV‐1 virological suppression. Cabotegravir And Rilpivirine Implementation Study in European Locations (CAR
Externí odkaz:
https://doaj.org/article/cf663c19fbc04c13b44fe74a60666e97
Autor:
Stephane De Wit, Agathe Rami, Fabrice Bonnet, Rebecca DeMoor, Gilda Bontempo, Christine Latham, Martin Gill, Monica Hadi, Owen Cooper, Savita Bakhshi Anand, Cassidy Gutner, Mounir Ait-Khaled, Jean A van Wyk, Maggie Czarnogorski
Publikováno v:
Open Forum Infectious Diseases. 9
Background Cabotegravir + Rilpivirine Long Acting (CAB+RPV LA) every 2 months is a recommended regimen in European and US treatment guidelines for PLWH with virological suppression and no known resistance to CAB or RPV. CARISEL, an implementation stu